Chengdu Yazhong Bio-Pharmaceutical Co., Ltd.

Main research objective: In accordance with relevant bioequivalence testing regulations, sacubitril/valsartan sodium tablets (trade name: Novartis®, specification: 200mg (sacubitril 97mg/valsartan 103mg)) manufactured and supplied by Novartis Pharma Schweiz AG, were selected as the reference formulation. A fasting-administered human bioequivalence study was conducted on the test formulation, sacubitril/valsartan sodium tablets (specification: 200mg (sacubitril 97mg/valsartan 103mg)) manufactured and supplied by Chengdu Yazhong Biopharmaceutical Co., Ltd., to compare whether the differences in the absorption rate and extent of the drug in the test formulation with those in the reference formulation were within acceptable ranges, and to evaluate the bioequivalence of the two formulations under fasting administration conditions. Secondary study objective: To observe the safety of oral administration of the investigational formulation sacubitril/valsartan sodium tablets (200 mg (sacubitril 97 mg/valsartan 103 mg)) and the reference formulation sacubitril/valsartan sodium tablets (trade name: Nosint®, 200 mg (sacubitril 97 mg/valsartan 103 mg)) in healthy trial participants.